The EDTA https://www.selleckchem.com/products/R788(Fostamatinib-disodium).html sample was placed on ice immediately. The LH whole blood sample was measured for ionized calcium (iCa; pH 7.4 corrected values), haemoglobin (Hb) and pH within 10 min of buy ABT-888 collection (ABL77 blood gas analyser, Radiometer, Brønshøj, Denmark), and the remaining sample was then placed on ice. Plasma was separated within 1 h of collection in a refrigerated centrifuge at 1,800 g for 20 min, and

aliquots were stored at −70 °C. Urine was collected in acid-washed containers, mixed thoroughly. Non-acidified and acidified (concentrated hydrochloric acid (HCl), 10 ml/l, laboratory reagent grade, SG 1.18, Fisher Scientific) aliquots were taken and stored at −20 °C. After completion of the study, plasma and urine samples were packed and shipped on dry ice to MRC Human Nutrition Research, Cambridge and subsequently stored at −80 °C until analysis. LH AR-13324 molecular weight plasma was used for the measurement of 1,25(OH)2D

(radioimmunoassay IDS Ltd., Tyne and Wear, UK), 25-hydroxyvitamin D (25(OH)D), bone-specific alkaline phosphatase (BALP), osteocalcin (OC) (all chemiluminescent immunometric automated assays, CLIA; DiaSorin, Stillwater, MN, USA), β C-terminal cross-linked telopeptide of type 1 collagen (βCTX) (ELISA, IDS Ltd., Tyne & Wear, UK), cAMP (ELISA, R&D Systems, Abington, UK), total calcium (tCa), phosphate (P), creatinine (Cr) and albumin (Alb) (colorimetric methods, Kone Lab 20i clinical chemistry analyser platform, Kone Espoo, Finland). EDTA plasma was used for the measurement of PTH by immunoassay (Immulite, Siemens Healthcare Diagnostics Ltd, Camberley, UK). Urinary (u) calcium (uCa), phosphate (uP) and creatinine (uCr) were measured in acidified urine (colorimetric methods, Kone Lab 20i, as above). Concentrations of uCa and uP were expressed as a ratio relative to uCr to adjust for urinary volume. Urinary cAMP was measured in non-acidified urine (ELISA, R&D Systems, as above). All assays except PTH (between-assay

coefficient of variation (CV), 4.7 %) were performed in duplicate. Assay performance was monitored using kit and in-house controls and under strict standardisation according to ISO 9001:2000. Quality assurance of 25(OH)D and 1,25(OH)2D assays were performed as part of the Vitamin D External Quality Assessment Scheme (www.​deqas.​org) and PTH assays as part of the National External Quality Cell press Assessment Scheme (www.​ukneqas.​org.​uk), and all were within accepted limits. Within- and between-assay CVs for 1,25(OH)2D were 7.5 and 9.0 %. Cross-reactivity of the assay is 100 and 91 % for 1,25(OH)2D3 and 1,25(OH)2D2, respectively. Cross-reactivity of the 25(OH)D assay is 100 and 104 % for 25(OH)D3 and 25(OH)D2, respectively. Within- and between-assay CVs were 3.7 and 2.9, 1.6 and 3.6, and 3.8 and 4.0 % for 25(OH)D, BALP and OC, respectively. The within- and between-assay CVs for βCTX were 2.9 and 1.4 %. Within- and between-assay CVs for all Kone assays were <2 and <4 %, respectively. Within- and between-assay CVs for pcAMP and ucAMP were 6.